Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Out of 161 patients, 124 patients presented with IDC and 37 with ILC. Patients with ILC were less likely to have a pCR (3% vs. 20%, P < 0.009) and breast conserving surgeries (51% vs. 79%, P < 0.001). Patients with ILC tended to have oestrogen receptor positive tumors (86% vs. 52%, P < 0.0001), HER 2 negative tumors (69% vs. 84%), and lower nuclear grade (nuclear grade 3, 16% vs. 46%, P < 0.001). Patients with ILC tended to have longer time to progression ( TTP) (42 months vs. 26 months) and overall survival (69 months vs. 65 months). CONCLUSIONS: Our results indicate that patients with ILC achieved a lower pCR rate and ineligibility for BCS to preoperative chemotherapy, but this did not result in a survival disadvantage. Because of these results new strategies to achieve a pCR are warranted.
|
Authors | Catharina Wenzel, Rupert Bartsch, Dagmar Hussian, Ursula Pluschnig, Gabriela Altorjai, Christoph C Zielinski, Alois Lang, Anton Haid, Raimund Jakesz, Michael Gnant, Guenther G Steger |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 104
Issue 1
Pg. 109-14
(Jul 2007)
ISSN: 0167-6806 [Print] Netherlands |
PMID | 17061042
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Taxoids
- Granulocyte Colony-Stimulating Factor
- Docetaxel
- Doxorubicin
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Austria
(epidemiology)
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Carcinoma, Ductal, Breast
(drug therapy, mortality, pathology)
- Carcinoma, Lobular
(drug therapy, mortality, pathology)
- Disease-Free Survival
- Docetaxel
- Doxorubicin
(administration & dosage)
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Survival Analysis
- Taxoids
(administration & dosage)
- Treatment Outcome
|